The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Approximately 1 million Australian adults have Type 2 diabetes and it is estimated over 2 million people are pre-diabetic or are at high risk of developing the ...

SAN FRANCISCO--(BUSINESS WIRE)--Navis World Conference — Navis, a part of Cargotec Corporation, and the provider of operational technologies and services that unlock greater performance and efficiency ...

CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). This next generation angiogenesis inhibitor has completed a ...